Provectus Biopharmaceuticals, Inc. (the Company) is extending
the expiration date of its previously announced offer to certain of its holders of outstanding warrants to purchase shares of common stock, $0.001 par value per share (Common Stock), issued between November 2011 and December 2015 (the
Existing Warrants) to receive new warrants expiring June 19, 2020 to purchase an equal number of shares of our Common Stock at an exercise price of $0.85 per share (the Replacement Warrants) in exchange for exercising
their Existing Warrants at a discounted exercise price of $0.75 per share (the Warrant Exchange Offer).
The Warrant Exchange
Offer was previously set to expire at 4:00 P.M. (Eastern time) on Tuesday, June 28, 2016 and will now expire at 4:00 P.M. (Eastern time) on Thursday, July 28, 2016, unless further extended or terminated. As of June 27, 2016,
no Existing Warrants have been tendered for exchange in the Warrant Exchange Offer.
All other terms and conditions of the Warrant
Exchange Offer will remain in full force and effect. The terms and conditions of the Warrant Exchange Offer are set forth in the Offer Letter/Prospectus dated June 1, 2016 (the Offer Letter/Prospectus), filed with the Securities and
Exchange Commission (the SEC) on June 1, 2016. Questions relating to the procedure for tendering Existing Warrants, as well as requests for additional copies of the Offer Letter/Prospectus and the Letter of Transmittal, may be
directed to Maxim Group LLC, Network 1 Financial Securities, Inc. or the Company using the contact information below:
Maxim Group LLC
Attn: Summer Kotb
405 Lexington Avenue, 2nd Floor
New York, NY 10174
Phone: (212) 895-3511
Email: skotb@maximgrp.com
Network 1 Financial Securities, Inc.
Attn: William Heming Jr.
2 Bridge Avenue
Red Bank, NJ 07701
Phone: 1 (800) 866-7007
Email: billheming@netw1.com
Provectus Biopharmaceuticals, Inc.
Attn: Peter R. Culpepper
7327 Oak Ridge Highway, Suite A
Knoxville, TN 37931
Phone: (866) 597-5999
Email: pete@pvct.com
FORWARD-LOOKING STATEMENTS: This Current
Report on Form 8-K contains forward-looking statements as defined under U.S. federal securities laws. These statements reflect managements current knowledge, assumptions, beliefs, estimates, and expectations and express
managements current views of future performance, results, and trends and may be identified by their use of terms such as anticipate, believe, could, estimate, expect,
intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual
results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such
statements after this date.